CN104666366A - Infection-inhibiting composition and food and drink containing composition - Google Patents
Infection-inhibiting composition and food and drink containing composition Download PDFInfo
- Publication number
- CN104666366A CN104666366A CN201310642577.8A CN201310642577A CN104666366A CN 104666366 A CN104666366 A CN 104666366A CN 201310642577 A CN201310642577 A CN 201310642577A CN 104666366 A CN104666366 A CN 104666366A
- Authority
- CN
- China
- Prior art keywords
- infection
- food
- composition
- isotoadstool
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an infection-inhibiting composition employing heated bacteria of a heterotrophic agaric extract and lactic acid bacteria as effective components, and food and drink containing the composition. The food and drink shows a good inhibiting effect on infection of pathogenic bacteria and the like after being orally taken. The composition contains 0.5-99.5wt% of an extract of heterotrophic agaric fruiting body and/or mycelium culture and 99.5-0.5wt% of heated bacteria of lactic acid bacteria; and one part of food and drink contains 0.005-2g of infection-inhibiting composition. According to the infection-inhibiting composition, a cell immune system employing macrophage, an NK cell and a T cell as centers can be activated; and the pathogenic bacteria are effectively eliminated.
Description
Technical field
The present invention relates to the heat treated thalline of isotoadstool extract and lactobacillus be effective ingredient suppression infected group compound and diet product containing said composition.
Background technology
As everyone knows, the isotoadstool (Agaricus blazei Murill) belonging to Basidiomycetes Agaricaceae fungus has cancer, anaphylaxis, diabetes, the composition of the prevention and therapy effect of hypertension etc., such as, as anti-tumor active ingredient, acidic polysaccharose body (clear No. 64-67194 of Japanese Laid Open Patent) can be isolated respectively from its sporophore, neutral polysaccharide body (clear No. 64-67195 of Japanese Laid Open Patent) and proteoglycan body (flat No. 2-78630 of Japanese Laid Open Patent), proteoglycan body (clear No. 61-47518 of Japanese Laid Open Patent) is isolated from mycelium, proteoglycan body (clear No. 61-47519 of Japanese Laid Open Patent) is isolated further from mycelial culturing filtrate.
Isotoadstool is widely used as health food raw material.Such as, No. 2001-103927, Japanese Laid Open Patent discloses use solvent under an increased pressure and extracts gill fungi, then processes this extract with the ethanol of 50%, then gained gill fungi extractum is mixed into food and obtained edible composition.
No. 2001-17130, Japanese Laid Open Patent discloses the healthy beverage food containing gill fungi, and the feature of this healthy beverage food has been mixed into vinegar and Mel in the decocting liquid of gill fungi.
Flat No. 11-32723 of Japanese Laid Open Patent discloses and utilizes enzyme based on hemicellulase to carry out resolution process to the mycelium of gill fungi, sporophore and their mixture or their cultivation residual liquid, obtain p mono-glucosan, the health food being main constituent with the biological active substances containing a large amount of this B mono-glucosan.
In addition, lactobacillus is also extensively absorbed as health food, have improve intestinal flora balance, reduce the generation of enteral putrefaction, improve the effect of feces character and immune activation.Such as, the immunomodulator that it is main constituent that No. 2001-48796, Japanese Laid Open Patent discloses with the dead thalline of enterococcus faecalis AD101 bacterial strain.
The flat No. 10-29946 humoral immunization restorative that to disclose with lactobacillus or its handled thing be effective ingredient of Japanese Laid Open Patent, this restorative has the effect of the humoral immunization functional recovery making to decline because of medicament.Flat No. 6-80575 of Japanese Laid Open Patent discloses and contains with lactobacillus thalline and/or thalline the peroral immunity activator that thing is effective ingredient.
The flat No. 5-252900 immune activation compositions disclosing the cytoplasmic components that comprises lactobacillus thalline and/or cytoplasmic components and contain thing of Japanese Laid Open Patent.
Summary of the invention
Isotoadstool and lactobacillus are widely used as health food, but physiologic effect when they are ingested separately is unsatisfactory.
Therefore, the object of this invention is to provide oral uptake and can show the suppression infected group compound of good inhibition and the diet product containing said composition to the infection of pathogen etc.
In order to achieve the above object, and with the extract of isotoadstool and the heat treated thalline of lactobacillus, stronger inhibitory action can be shown to the infection of pathogen.
Suppress infected group compound, the feature of said composition is containing the heat treated thalline as the sporophore of the isotoadstool of effective ingredient and/or the extract of Mycelium culture and lactobacillus.The synergy of the immunity effect activity utilizing the heat treated thalline of the sporophore of isotoadstool and/or the extract of Mycelium culture and lactobacillus to possess, provides and shows suppression infected group compound compared with high inhibition effect to the infection of pathogen etc.
Lactobacillus is enterococcus faecalis (EnterococCUS faecalis) preferably, in addition, the sporophore of aforementioned isotoadstool (Agaricus blazei Murill) preferably containing 0.5 ~ 99.5 quality % and/or the heat treated thalline of the extract of Mycelium culture and the aforementioned lactobacillus of 99.5 ~ 0.5 quality %.Can provide like this can more effectively to the suppression infected group compound that the infection of pathogen etc. suppresses.
Another kind of invention provides the diet product containing above-mentioned suppression infected group compound.The content suppressing infected group compound to correspond to 1 meal part is 0.01 ~ 10g, is preferably 0.005 ~ 2g.
Because the heat treated thalline containing the sporophore of isotoadstool taken in as food and/or the extract of Mycelium culture and lactobacillus is as effective ingredient in suppression infected group compound of the present invention, so safety is high than ever, by taking in above-mentioned extract and heat treated thalline, good infection mitigation effect can be produced to pathogen etc.Suppression infected group compound of the present invention is added in diet product, the diet product of the infection that can prevent pathogen etc. can be provided.
Although the mechanism of action of the current also suppression infectious effect of suppression infected group compound clearly not of the present invention, but by taking in the heat treated thalline of the sporophore of isotoadstool and/or the extract of Mycelium culture and lactobacillus simultaneously, the cell immune system centered by macrophage, NK cell and T cell can be made to activate, effective excluding pathogenic bacteria etc.
Accompanying drawing explanation
Fig. 1 represents the measurement result of the Listeria monocytogenes number in the mouse spleen after infecting Listeria monocytogenes.
Fig. 2 represents the cytokine amount (IL-2, IL-10, IL-12, IFN-Y) in the supernatant of Mesenteric lymph node cell (MLN) culture fluid measured by ELISA method.
Detailed description of the invention
Sporophore extract as the isotoadstool of one of the effective ingredient of suppression infected group compound of the present invention directly can extract acquisition by water, ethanol equal solvent, and also available water, ethanol equal solvent extract its dry thing and obtain.Such as, add the water of about 20 times of dry isotoadstool sporophore quality, carry out extraction in 30 minutes in 120 DEG C, then gained extract is suitably concentrated and drying.
In addition, can cultivate the kind bacterium of isotoadstool in the culture medium containing carbon source and nitrogenous source, then directly extraction and obtain the extract of the Mycelium culture of isotoadstool, or as previously mentioned its dry product be extracted.
The present invention also can use commercially available isotoadstool sporophore and/or the extract of Mycelium culture.
Heat treated thalline as the lactobacillus of another effective ingredient of suppression infected group compound of the present invention is the dead thalline carrying out heat treated to lactic acid thalline and obtain, such as, obtain by following methods.
In the medium, after 12 ~ 72 hours being cultivated to lactobacillus in 30 ~ 45 DEG C, thalline is reclaimed by suitable means such as centrifugalize.The thalline reclaimed is washed and concentrated, after 80 ~ 115 DEG C of thallus suspension liquids concentrated this carry out the heat treated in 30 minutes ~ 3 seconds, carries out drying by the suitable means such as spraying dry and lyophilization and obtain above-mentioned dead thalline.Above-mentioned lactobacillus comprises enterococcus faecalis, enterococcus faecalis, bacillus acidophilus, lactobacillus casei, Deshi Lactobacillus, lactobacillus helveticus, bifidobacterium longum, bifidobacterium breve, saliva chain coccus thermophilous subspecies etc.The present invention preferably uses the enterococcus faecalis (ATCC19433, ATCC14508, ATCC23655) with stronger immunity effect activity.The heat treated thalline of spendable enterococcus faecalis comprises the commercially available product such as EFPOWER, EF-2001 (trade name, Konbe K.K's system) and FK-23 (trade name, koqikoqi Pharmaceutical Co., Ltd system).
The heat treated thalline of the sporophore of aforementioned isotoadstool of 0.5-99.5 quality % and/or the aforementioned lactobacillus of the extract of Mycelium culture and 99.5 ~ 0.5 quality % is preferably comprised in the suppression infected group compound of invention.Be more preferably the heat treated thalline of the lactobacillus of the sporophore of the isotoadstool comprising 10 ~ 90 quality % and/or the extract of Mycelium culture and 90 ~ 10 quality %.If the content of each effective ingredient is outside above-mentioned scope, then the collaborative infectious effect that suppresses is undesirable.
In suppression infected group compound of the present invention except comprising above-mentioned basis, also can comprise excipient, sweeting agent, acidic flavoring agent, vitamin and mineral.In addition, being not particularly limited its form, can be powder, granule, tablet, capsule, solution etc., can do suitably to select according to the difference of application target.
Effective intake of suppression infected group compound of the present invention is adult 1 day is 0.05 ~ 2g.
Suppression infected group compound of the present invention can add in various diet product, such as, and beverage, frozen glue, confection, chewing gum, can heated food, fast food etc.It is 0.005 ~ 2g that the addition of above-mentioned suppression infected group compound corresponds to 1 meal part.If suppress the addition of infected group compound less than 0.01g, enough suppression infectious effects can not be obtained even if then take in, if more than 10g, then high cost.
Below, by embodiment, the present invention is specifically described.Sample in following example is used as " celestial raw dew " (trade name of the sporophore extract of isotoadstool, Kyowa Eng's system) and " EF-2001 " (trade name, the Konbe K.K's system) of heat treated thalline as enterococcus faecalis (Enterococcus faecalis).
Test example (the acute oral toxicity test of the heat treated thalline of enterococcus faecalis)
With OECD Guide, " nes for the Chemicals401 (1981), for benchmark, carries out acute oral toxicity test with mice.
Specifically, the heat treated thalline of enterococcus faecalis is suspended in Purified Water, modulates testing liquid (250mg/mL).After pouring into above-mentioned testing liquid and Purified Water, within 1 day, observe 1 time (observation period is 14 days), two groups all there is not dead example.Observation period terminates to dissect all mices afterwards, its main organs also no abnormality seen.
In addition, within after pouring into testing liquid and Purified Water the 7th day and the 14th day, measure Mouse Weight, by t method of inspection with the comparison between significance level 5% group, its result is as shown in table 1.
Table 1
Body weight is represented by mean+SD (n=10)
As can be seen from Table 1, increase variant no matter each group of male and female are showed no body weight.Can find out from the above results, a per os takes in the LD of the mice of the heat treated thalline of enterococcus faecalis
50value is more than 5000mg/kg body weight.
Embodiment 1
The BALB/c female mice in 40 7 week ages is divided into 4 groups (often organizing 10), respectively with gastric probe to the mixture of the mice of test group sporophore extraction extractum (dry sporophore 0.3mg/ only) of oral administration isotoadstool and the heat treated thalline (10ug/) of enterococcus faecalis by force, to the heat treated thalline (20ug/ only) of the mice of comparable group 1 oral administration enterococcus faecalis by force, to sporophore extraction extractum (dry sporophore 0.6mg/ only) of the mice of comparable group 2 oral administration isotoadstool by force, to the mice of matched group by force oral administration with PBS (0.2mL/ only), every day 1 time in 1 week.
Then, in mouse peritoneal, inject Listeria monocytogenes (Listeriamonocytogenes), reach 2X10
5cFU/ only, observes the survival rate of each group of mice.Duration of test, mice freely can take in water and feedstuff (trade name " powder feed CE-2 ", sunset kenea Co., Ltd. of Japan system).
Its result as shown in Figure 1.As can be seen from Figure 1, test group, comparable group 1 compared with matched group, show very high survival rate with 2.Particularly the mice of test group does not have 1 death, the infection of this instruction book monocytogenes and propagation obtain and suppress embodiment 2 similarly to Example 1, from test first 1 week every day make each group of mice oral administration sample by force for 1 time, then make mouse infection Listeria monocytogenes.Then, win the spleen of mice, measure the change of the Listeria monocytogenes number that spleen infects.Specifically, within after infection the 1st, 3,5,7 day, win spleen, after spleen is ground, be suspended in PBS, after suspension is progressively diluted, moved into " enriched medium of Listeria monocytogenes " (trade name, MERCK Inc.) in carry out cultivating (25 DEG C, 48 hours), measure the clump count occurred, its result is as shown in Figure 1.
As can be seen from Figure 1, after infecting, after the 3rd day, the Listeria monocytogenes quantity of matched group increases, and the bacterium number of test group, comparable group 1 and 2 reduces, and particularly the bacterium number of test group reduces large percentage.
Can find out from these results, the heat treated thalline of sporophore extraction extractum and enterococcus faecalis that per os takes in isotoadstool is simultaneously compared with they are individually taken in, and the former shows and better suppresses infectious effect.
Embodiment 3
Suppression infection effect mechanism when by the following method per os being taken in simultaneously to sporophore extraction extractum and the heat treated thalline of enterococcus faecalis of isotoadstool is inquired into.
(1) after the surface antigen parsing quarantine examination of CD3 positive d p-type T cell terminates, BALB/c mouse (the female 7 week age of preparation raising in 1 week will be have passed through, qiluniba mono-Co., Ltd. buys) be divided into 2 groups (often organizing 3), respectively with gastric probe to the mixture (0.2mL/) of the mice of test group sporophore extraction extractum (dry sporophore 0.2mg/ only) of oral administration isotoadstool and the heat treated thalline (20ug/ only) of enterococcus faecalis by force, to the mice of matched group by force oral administration with PBS (0.2mL/ only), every day 1 time in 1 week.Then, enter Listeria monocytogenes from the tail vein injection of mice, reach 1.4X10
4cFU/ only.Between feeding period, mice freely can take in water and feedstuff (trade name " powder feed CE-2 ", Japan sunset L fourth Co., Ltd. system).
The mice killing each group on the 5th day after inoculation Listeria monocytogenes, win its mesenteric lymph node, mesenteric lymph node is clamped with clouded glass, it is made to be suspended in RPMI-1640 culture fluid (trade name containing 10%FBS, Invitrogen system), remove unnecessary tissue with stainless steel mesh after washing, modulate the Mesenteric lymph node cell (hereinafter referred to as MLN) of test group and matched group respectively.
Make each MLN be suspended in containing 10% FBS RPMI-1640 culture fluid in, reach 5X10
5individual/mL, adds 1mL culture fluid in every 1 hole of 6 orifice plates (Corning Costar Co. system).Then,
Splenocyte (the 5X10 from undressed BALB/c mouse through processing as the ametycin (consonance fermentation industry system) of stimulus object is mixed in every 1 hole
5individual) and the dead thalline (1.0X10 of heating of Listeria monocytogenes
6cFU), in 37 DEG C 5% CO
2there are lower cultivation 48 hours.
Above-mentioned undressed mice refers to and not to take for examination material and without the mice of microbionation.
With following 3 kinds of traget antibodies (antibody is all bought by Becton Dickinson PharMingen company), each MLN is dyeed, carry out the parsing of cell surface antigen.
1) the anti-CD4mAb/biotin of Cy-chrome (Cy) labelling AntiCD3 McAb ε mAb/FITC labelling anti-tcr α β mAb/PE labelling marks ten own anti-CD8mAb
2) { own AntiCD3 McAb ε mAb/FITC marks { the anti-CD8mAb of own anti-tcr d mAb/PE labelling anti-CD 6 9mAb/biotin labelling to Cy mark
3) { namely the anti-CD8mAb of own anti-tcr Q mAb/PE labelling anti-CDl22mAb/biotin labelling, is being modulated into 1.0*10 to Cy labelling AntiCD3 McAb ε mAb/FITC mark
55uL above-mentioned 1 is added in the suspension of individual MLN) traget antibody that represents, in 4 DEG C of insulations after 45 minutes, with Hank ' the s buffer solution containing 5%FBS 2 times, add the SA-RED613 (trade name of 5uL again, Invitrogen Inc.), in 4 DEG C of insulations after 45 minutes, Hank ' the s buffer solution of use containing 5%FBS 3 times.Then, the surface antigen being carried out MLN by flow cell analyzer (EpicsXL, Beckman Coulter lnc. system) is resolved, and tries to achieve CD4
-cD8
+cell and CD4
-cD8
+the ratio of cell, compares CD8 positive rate, and its result as shown.
Table 2
As can be seen from Table 2, about high about 2 times than matched group of the CD8 positive rate of test group, this illustrates that the heat treated thalline of sporophore extraction extractum and the enterococcus faecalis taking in isotoadstool improves CD8 positive rate.
In addition, with the presence or absence that CD69 (initial activity labelling) and CD122 (1L-2 receptor β chain) activates for index study CD8 positive T cell.That is, above-mentioned 2 are used) and 3) traget antibody that represents, the surface antigen being carried out cell by method similar to the above is resolved, and its result is as shown in table 3.
As can be seen from Table 3, CD69 and the CD122 positive rate of test group is all than the height of matched group, and this illustrates that the heat treated thalline of sporophore extraction extractum and the enterococcus faecalis taking in isotoadstool facilitates the activation of CD8 positive T cell.
Table 3
(2) output of cytokine
Modulate the MLN of matched group and test group as described above, add stimulus object, in 37 DEG C at 5%CO
2the cultivation of 48 hours is carried out under existence.
Cultivation terminates rear recovery culture supernatant, measures the cytokine amount (IL-2, IL-10, IL-12, IFN-Y) in culture supernatant by ELISA method.IL-2, IL-12 and IFN-Y is measured, with from state by the determination box bought from Endogen lnc. company ' determination box bought of ALYZA TECHNE Co. company measures IL-10, and its result is as shown in Figure 2.
As can be seen from Figure 2, the output of IFN-Y and IL-12 as t helper cell 1 (Th-1) cytokines of test group is very high, and the output as the IL-10 of t helper cell 2 (Th-2) cytokines is very low.
With the expression of RT-PCR method research cytokine mRNA, found that the expression of the mRNA of Th-1 cytokines I1-12, IFN-Y and TNF-d of test group increases.The expression indifference of the mRNA of Th-2 cytokines-10.
Generally, activated by macrophage and NK cell in the body of the cytozoicus bacteriological infection such as Listeria monocytogenes, produced IL-12 and IFN-Y respectively.These cytokines make bacterial antigens again
Specific CD8 positive T cell activation, the CD8 positive T cell consequently with cytotoxicity (CTL) completes antibacterial and gets rid of.In addition, the TNF-Q produced by T cell has the effect making the phagocyte such as neutrophilic granulocyte and macrophage be gathered in infection site.
Namely, can find out from the above results, by sporophore extractum and enterococcus faecalis also with isotoadstool, more facilitate the activation of macrophage and NK cell, the output of IL-12 and IFN-Y etc. is increased, further promote the activation of Listeria monocytogenes specific C D8 positive cell, also comparatively matched group is fast in antibacterial eliminating simultaneously.
As mentioned above, the invention provides and have the good compositions suppressing infectious effect, said composition contains the heat treated thalline of the sporophore of isotoadstool and/or the extract of Mycelium culture and enterococcus faecalis as effective ingredient.In addition, additionally provide the diet product of the infection that can prevent pathogen etc., in these diet product, with the addition of suppression infected group compound of the present invention.
Suppression infected group compound of the present invention is owing to deriving from food, so safety is higher, after taking in, expection can promote the activation of the body defending system centered by cellular immunization, has the effect of the infection of prevention pathogen etc.
Claims (3)
1. suppress infected group compound, containing the heat treated thalline as the sporophore of the isotoadstool of effective ingredient and/or the extract of Mycelium culture and lactobacillus, it is characterized in that, the heat treated thalline of the aforementioned lactobacillus of the sporophore of described isotoadstool containing 0.5 ~ 99.5 quality % and/or the extract of Mycelium culture and 99.5 ~ 0.5 quality %.
2. suppression infected group compound as claimed in claim 1, it is characterized in that, described lactobacillus is enterococcus faecalis.
3. diet product, the suppression infected group compound that described diet product contain according to any one of claims 1 to 3 is characterized in that, 1 meal part is contained described in 0.005 ~ 2g and suppressed infected group compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642577.8A CN104666366A (en) | 2013-12-03 | 2013-12-03 | Infection-inhibiting composition and food and drink containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642577.8A CN104666366A (en) | 2013-12-03 | 2013-12-03 | Infection-inhibiting composition and food and drink containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104666366A true CN104666366A (en) | 2015-06-03 |
Family
ID=53302302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310642577.8A Withdrawn CN104666366A (en) | 2013-12-03 | 2013-12-03 | Infection-inhibiting composition and food and drink containing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104666366A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143782A (en) * | 2023-10-30 | 2023-12-01 | 杭州微致生物科技有限公司 | Streptococcus salivarius thermophilus VB331 and application thereof |
-
2013
- 2013-12-03 CN CN201310642577.8A patent/CN104666366A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117143782A (en) * | 2023-10-30 | 2023-12-01 | 杭州微致生物科技有限公司 | Streptococcus salivarius thermophilus VB331 and application thereof |
| CN117143782B (en) * | 2023-10-30 | 2024-03-22 | 杭州微致生物科技有限公司 | Streptococcus salivarius thermophilus VB331 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7012840B2 (en) | Lactic acid bacteria and their uses | |
| CN105087423B (en) | Novel Bei Laisi bacillus CJBV and the bactericidal composition containing it | |
| Nayak | Probiotics and immunity: a fish perspective | |
| Kim et al. | Lactococcus lactis BFE920 activates the innate immune system of olive flounder (Paralichthys olivaceus), resulting in protection against Streptococcus iniae infection and enhancing feed efficiency and weight gain in large-scale field studies | |
| KR101095712B1 (en) | Lactic Acid Bacteria Having Mucosal Immunopotentiation Effect | |
| Al Kassaa | NEW INSIGHTS ON ANTIVIRAL PROBIOTICS. | |
| Guluarte et al. | Probiotic properties and fatty acid composition of the yeast Kluyveromyces lactis M3. In vivo immunomodulatory activities in gilthead seabream (Sparus aurata) | |
| JP4712289B2 (en) | Immune promoting composition | |
| KR102121946B1 (en) | Composition for treating or preventing of arthritis, fibrosis, colitis or transplant rejection comprising Lactobacillus Acidophilus | |
| TW201902499A (en) | COMPOSITION FOR ACTIVATING Toll-LIKE RECEPTOR 2 | |
| JP4499979B2 (en) | Composition for controlling pathogen infection | |
| CN105899090A (en) | Intestinal barrier function enhancer containing lactic acid bacteria | |
| Farid et al. | Saccharomyces cerevisiae | |
| Safari et al. | Powder of the white bottom mushroom, Agaricus bisporus (Agaricomycetes), improved immunomodulatory and health-promoting effects of Lactobacillus casei in zebrafish (Danio rerio) | |
| CN104666366A (en) | Infection-inhibiting composition and food and drink containing composition | |
| CN103751223A (en) | Infection-suppressing composition, and food containing the same | |
| CN1269490C (en) | Composition of suppressing infection, and veberage and food contg. same | |
| KR101655854B1 (en) | Lactobacillus casei CBG-C16 strain producing conjugated linoleic acid and uses thereof | |
| JP6117336B2 (en) | Newly isolated Bacillus licheniformis and probiotics using it | |
| Nikapitiya | Marine bacteria as probiotics and their applications in aquaculture | |
| KR101655853B1 (en) | Lactobacillus reuteri CBG-C15 strain producing conjugated linoleic acid and uses thereof | |
| KR101664306B1 (en) | Lactobacillus fermentum CBG-C17 strain producing conjugated linoleic acid and uses thereof | |
| KR101655851B1 (en) | Lactobacillus acidophilus CBG-C13 strain producing conjugated linoleic acid and uses thereof | |
| KR101655852B1 (en) | Lactobacillus rhamnosus CBG-C14 strain producing conjugated linoleic acid and uses thereof | |
| KR101655855B1 (en) | Lactococcus lactis CBG-C18 strain producing conjugated linoleic acid and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150603 |